PD-1/PD-L1 blockade in renal cell cancer

被引：25
|
作者：
Beckermann, Kathryn E. [1 ]
Johnson, Douglas B. [1 ]
Sosman, Jeffrey A. [2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA
[2] Northwestern Univ, Med Ctr, Dept Med, Chicago, IL 60611 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2017年 / 13卷 / 01期
关键词：
Renal cell; PD-1; PD-L1; nivolumab; atezolizumab; pembrolizumab; HYPOXIA-INDUCIBLE FACTOR; LONG-TERM SAFETY; PD-L1; EXPRESSION; SPONTANEOUS REGRESSION; CLINICAL ACTIVITY; CARCINOMA; NEPHRECTOMY; ANTIBODY; PATIENT; TUMOR;
D O I：
10.1080/1744666X.2016.1214575
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC.Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC.Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.
引用
收藏
页码：77 / 84
页数：8
相关论文
共 50 条
  • [1] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    [J]. ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [2] New strategies with PD-1/PD-L1 blockade in lung cancer
    不详
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (SUPPL 3) : 54 - 58
  • [3] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    [J]. ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
  • [4] PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
    Yaghoubi, Neda
    Soltani, Arash
    Ghazvini, Kiarash
    Hassanian, Seyed Mahdi
    Hashemy, Seyed Isaac
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 312 - 318
  • [5] PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
    Hosseinzadeh, Ramin
    Feizisani, Fahimeh
    Shomali, Navid
    Abdelbasset, Walid Kamal
    Hemmatzadeh, Maryam
    Gholizadeh Navashenaq, Jamshid
    Jadidi-Niaragh, Farhad
    Bokov, Dmitry O.
    Janebifam, Morteza
    Mohammadi, Hamed
    [J]. IUBMB LIFE, 2021, 73 (11) : 1293 - 1306
  • [6] PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer
    Polak, Paz
    Fu, Lili
    Foulkes, William D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (09): : 866 - 868
  • [7] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Hamanishi, Junzo
    Mandai, Masaki
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Konishi, Ikuo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (03) : 462 - 473
  • [8] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi
    Masaki Mandai
    Noriomi Matsumura
    Kaoru Abiko
    Tsukasa Baba
    Ikuo Konishi
    [J]. International Journal of Clinical Oncology, 2016, 21 : 462 - 473
  • [9] Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Shergold, Amy L.
    Millar, Rhona
    Nibbs, Robert J. B.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 145
  • [10] Toxicities Associated With PD-1/PD-L1 Blockade
    Wang, Daniel Y.
    Johnson, Douglas B.
    Davis, Elizabeth J.
    [J]. CANCER JOURNAL, 2018, 24 (01): : 36 - 40
12345